![Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit](https://www.researchgate.net/profile/Osvaldo-Aren/publication/350759389/figure/fig1/AS:1025533706006531@1621517697863/Subgroup-analysis-of-OS-in-the-PD-L1th-population-CI-confidence-interval-ECOG-PS_Q320.jpg)
Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit
![Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit](https://i1.rgstatic.net/ii/profile.image/359041135071232-1462613485394_Q512/Mustafa-Oezgueroglu.jpg)
Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit
![Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit](https://www.researchgate.net/publication/349102191/figure/tbl3/AS:1022715091771393@1620845687675/OS-based-on-the-primary-analysis-naive-sensitivity-analysis-and-IPCW-model_Q320.jpg)
Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit
![Safety Analysis Results for First-Line Durvalumab Plus Platinum/Etoposide in Extensive-Stage SCLC - The ASCO Post Safety Analysis Results for First-Line Durvalumab Plus Platinum/Etoposide in Extensive-Stage SCLC - The ASCO Post](https://ascopost.com/media/14012157/18-ozguroglu.jpg)
Safety Analysis Results for First-Line Durvalumab Plus Platinum/Etoposide in Extensive-Stage SCLC - The ASCO Post
![Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit](https://www.researchgate.net/publication/351409175/figure/tbl2/AS:1024793168064519@1621341139945/Treatment-emergent-Adverse-Events-Any-Grade-in-10-of-Total-Population-Related-to_Q320.jpg)
Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit
![Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit](https://www.researchgate.net/publication/349102191/figure/tbl2/AS:1022715091767297@1620845687644/Subgroup-analysis-of-subsequent-ICI-use-in-the-full-analysis-set_Q320.jpg)
Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit
![Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit Mustafa ÖZGÜROĞLU | Professor (Full) | professor | İstanbul University-Cerrahpaşa, Istanbul | Internal Medicine Division of Medical Oncology Clinical Trial Unit](https://www.researchgate.net/profile/Osvaldo-Aren/publication/350759389/figure/fig2/AS:1025533706006532@1621517697895/Objective-response-rate-and-duration-of-response-by-investigator-assessment-with-avelumab_Q320.jpg)